Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPd in Relapsed/Refractory Multiple Myeloma after KRd
NCT05509374Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Reversible Covalent Inhibitors, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, pomalidomide, dexamethasone in multiple myeloma (MM), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
carfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05509374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509374.